P53 Codon 72 and HER2 Codon 655 polymorphisms in Turkish breast cancer patients

DNA and Cell Biology

Volumn 29, Issue 7, 2010, Pages 387-392

  Kara, Nurten ^a   Karakus, Nevin ^a   Ulusoy, Ali Naki ^a   Ozaslan, Cihangir ^b   Gungor, Bulent ^a   Bagci, Hasan ^a  

^a ONDOKUZ MAYIS UNIVERSITY   (Turkey)

^b Research Hospital   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROLINE; PROTEIN P53; VALINE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER STAGING; CODON; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TURKEY (REPUBLIC);

BREAST; BREAST NEOPLASMS; CODON; FEMALE; GENE FREQUENCY; GENES, ERBB-2; GENES, P53; GENOTYPE; HOMOZYGOTE; HUMANS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROLINE; RECEPTOR, ERBB-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77953085145     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/dna.2009.0995     Document Type: Article

References (34)

1. Ameyaw, M.M., Tayeb, M., Thornton, N., Folayan, G., Tariq, M., Mobarek, A., Evans, D.A., Ofori-Adjei, D., and McLead, H.L. (2002). Ethnic variation in the HER-2 codon 655 genetic polymorphism previously associated with breast cancer. J Hum Genet 47, 172-175.
2. An, H.J., Kim, N.K., Oh, D., Kim, S.H., Park, M.J., Jung, M.Y., Kang, H., Kim, S.G., Lee, K.P., and Lee, K.S. (2005). Her2 V655 genotype and breast cancer progression in Korean women. Pathol Int 55, 48-52.
3. Ara, S., Lee, P.S., and Hansen, M.F. (1990). Codon 72 polymorphism of the TP53 gene. Nucleic Acids Res 18, 4691.
4. Baxter, S.W., and Campbell, I.G. (2001). Re: Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 93, 557-558.
5. Breast Cancer Association Consortium. (2006). Commonly studied single-nucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium. J Natl Cancer Inst 98, 1382-1396.
6. Buyru, N., Altinisik, J., Demokan, S., and Dalay, N. (2007). P53 genotypes and haplotypes associated with risk of breast cancer. Cancer Detect Prev 31, 207-213.
7. Buyru, N., Tigli, H., and Dalay, N. (2003). P53 codon 72 polymorphism in breast cancer. Oncol Rep 10, 711-714.
8. Damin, A.P.S., Frazzon, A.P.G., Damin, D.C., Roehe, A., Hermes, V., Zettler, C., and Alexandre, C.O.P. (2006). Evidence for an association of TP53 codon 72 polymorphism with breast cancer risk. Cancer Detect Prev 30, 523-529.
9. Dumont, P., Leu, J.I., Della Pietra, A.C., George, D.L., and Murphy, M. (2003). The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33, 357-365.
10. Harris, C.C. (1991). p53 at the crossroads of molecular carcino-genesis and risk assessment. Science 253, 49-53.
11. Harris, C.C., and Hollstein, M. (1993). Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 329, 1318-1327.
12. Hartmann, A., Blaszyk, H., Kovach, J.S., and Sommer, S.S. (1997). The molecular epidemiology of p53 gene mutations in human breast cancer. Trends Genet 13, 27-33.
13. Hsieh, Y.Y., and Lin, C.S. (2006). P53 codon 11, 72, and 248 gene polymorphisms in endometriosis. Int J Biol Sci 2, 188-193.
14. Kalemi, T.G., Lambropoulos, A.F., Gueorguiev, M., Chrisafi, S., Papazisis, K.T., and Kotsis, A. (2005). The association of p53 mutations and p53 codon 72, her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece. Cancer Lett 122, 57-65.
15. Kamali-Sarvestani, E., Talei, A.R., and Merat, A. (2004). Ile to Val polymorphism at codon 655 of HER-2 gene and breast cancer risk in Iranian women. Cancer Lett 215, 83-87.
16. Karakus, N., Kara, N., and Ulusoy, A.N. (2008). Lack of association between prohibitin 3 untranslated region C?T Polymorphism and breast cancer in a Turkish population. DNA Cell Biol 27, 449-452.
17. Keshava, C., McCanlies, E., Keshava, N., Wolff, M.S., and Weston, A. (2001). Distribution of HER2 V655 genotypes in breast cancer cases and controls in the United States. Cancer Lett 173, 37-41.
18. Lee, E.Y., Cibull, M.L., Strodel, W.E., and Haley, J.V. (1994). Expression of Her-2=neu oncoprotein and epidermal growth factor receptor and prognosis in gastric carcinoma. Arch Pa-thol Lab Med 118, 235-239.
19. Loging, W.T., and Reisman, D. (1999). Elevated expression of ribosomal protein genes L37, RPP-1, and S2 in the presence of mutant p53. Cancer Epidemiol Biomarkers Prev 8, 1011-1016.
20. Matlashewski, G.J., Tuck, S., Pim, D., Lamb, P., Schneider, J., and Crawford, L.V. (1987). Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 7, 961-963.
21. Millikan, R.C., Hummer, A.J., Wolff, M.S., Hishida, A., and Begg, C.B. (2005). Her2 codon 655 polymorphism and breast cancer: results from kin-cohort and case control analyses. Breast Cancer Res Treat 89, 309-312.
22. Nakajima, M., Sawada, H., Yamada, Y., Watanabe, A., Tatsumi, M., Yamashita, J., Matsuda, M., Sakaguchi, T., Hirao, T., and Nakano, H. (1999). The prognostic significance of amplification and overexpression of c-met and c-erB-2 in human gastric carcinomas. Cancer 85, 1894-1902.
23. Papewalis, J., Nikitin, A.Y.U., and Rajewsky, M.F. (1991). G to A polymorphism at amino acid codon 655 of the human erb-2= Her2 gene. Nucleic Acids Res 19, 5452.
24. Pim, D., and Banks, L. (2004). P53 polymorphism variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 108, 196-199.
25. Sjalander, A., Birgander, R., Hallmans, G., Cajander, S., Lenner, P., Athlin, L., Beckman, G., and Beckman L. (1996). P53 polymorphisms and haplotypes in breast cancer. Carcino-genesis 17, 1313-1316.
26. Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A., and McGuire, W.L. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER2=neu oncogene. Science 235, 177-182.
27. Sullivan, A., Syed, N., Gasco, M., Bergamaschi, D., Trigiante, G., Attard, M., Hiller, L., Farrell, P.J., Smith, P., Lu, X., and Crook, T. (2004). Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 23, 3328-3337.
28. Thomas, M., Kalita, A., Labrecque, S., Pim, D., Banks, L., and Matlashewski, G. (1999). Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 19, 1092-1100.
29. Tommiska, J., Eerola, H., Heinonen, M., Salonen, L., Kare, M., Tallila, J., Ristimäki, A., Von Smitten, K., Aittomä ki, K., Heikkilä, P., Blomqvist, C., and Nevanlinna, H. (2005). Breast cancer patients with p53 pro 72 homozygous genotype have a poorer survival. Clin Cancer Res 11, 5098-5103.
30. Toyama, T., Zhang, Z., Nishio, M., Hamaguchi, M., Kondo, N., Iwase, H., Iwata, H., Takahashi, S., Yamashita, H., and Fujii, Y. (2007). Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res 9, R34.
31. Turnbull, C., and Rahman, N. (2008). Genetic predisposition to breast cancer: past, present and future. Annu Rev Genomics Hum Genet 9, 321-345.
32. Xie, D., Shu, X.O., Deng, Z., Wen, W.Q., Creek, K.E., Dai, Q., Gao, Y.T., Jin, F., and Zheng, W. (2000). Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 92, 412-417.
33. Wang, L., Habuchi, T., Takahashi, T., Kamoto, T., Zuo, T., Mit-sumori, K., Tsuchiya, N., Sato, K., Ogawa, O., and Kato, T. (2002). No association between Her-2 gene polymorphism at codon 655 and a risk of bladder cancer. Int J Cancer 97, 787-790.
34. Wang, Y.C., Chen, C.Y., Chen, S.K., Chang, Y.Y., and Lin, P. (1999). P53 codon 72 polymorphism in Taiwanese lung cancer patients: association with lung cancer susceptibility and prognosis. Clin Cancer Res 5, 129-134.